Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
暂无分享,去创建一个
S. Chhabra | B. Dhakal | M. Mohan | A. Szabo | Lindsay Hammons | A. Janardan | Anita D’Souza | Meera Mohan
[1] P. Hari,et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma , 2021, Blood advances.
[2] Junnian Zheng,et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma , 2021, Blood advances.
[3] Chiung-Yu Huang,et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy , 2021, Blood advances.
[4] A. Krishnan,et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study , 2021, The Lancet.
[5] A. Chari,et al. Bispecifics, trispecifics, and other novel immune treatments in myeloma. , 2020, Hematology. American Society of Hematology. Education Program.
[6] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.